Within the growth area of cell and gene therapy (CGT), exciting new therapies are being developed, bringing with them new challenges and opportunities for the outbound supply chain.

In this podcast, Lesley talks about the needs and considerations of CGT supply chains and how they differ from traditional biopharmaceutical supply. She explores how important industry collaboration is and how we harness the expertise of our CGT Phorum to drive change.

BioPhorum members recognize the need to transform the performance of the global supply chain for biologics, and so a team of subject matter experts from across multiple companies is shaping a program of cross-industry collaboration to address topics ranging from capacity constraints, increased costs, and alignment on quality expectations of the outbound supply chain.

Lesley Holt, BioPhorum Supply Chain to Patient Director, talks about the needs and considerations of a sustainable outbound supply chain. How can your company benefit from collaboration with BioPhorum?

Colm Murphy came to the biopharmaceutical industry from the food industry, which has been dealing with farm-to-fork sustainability challenges for over a decade.

Through conversations within pharma and biotech, Colm feels like we are trying to reinvent the wheel rather than learn from those who have trodden the path before. With one of the biggest sustainability challenges centered around supply chains, how does Ipsen hope to take value by collaborating in BioPhorum Sustainability?

BioPhorum members recognize the need to transform the performance of the global supply chain for biologics, and so a team of subject matter experts from across multiple companies is shaping a program of cross-industry collaboration to address topics ranging from capacity constraints, increased costs, and alignment on quality expectations of the outbound supply chain.

Lesley Holt, BioPhorum Supply Chain to Patient Director, talks about data management and transparency, and the challenges this presents that affect biopharmaceutical logistics. What happens if the challenges are not addressed and what collaborations are expected across BioPhorum in order to tackle them?

BioPhorum members recognize the need to transform the performance of the global supply chain for biologics, and so a team of subject matter experts from across multiple companies is shaping a program of cross-industry collaboration to address topics ranging from capacity constraints, increased costs, and alignment on quality expectations of the outbound supply chain.

Lesley Holt, BioPhorum Supply Chain to Patient Director, talks about the complexity of the global supply chain for biologics, the trends she sees emerging, and how this differs from what we see in the news about how the supply chain impacts everyday items. How can your company benefit from collaboration with BioPhorum?

Cytiva's sustainability plan is a strategic intention to ensure that its policies, processes and collaborations across the value chain reflect its commitment to integrate sustainability throughout the business.

In this podcast, Emmanuel Abate, Vice President Genomics and Cellular Research and Sustainability Executive Leader, Cytiva, talks about BioPhorum providing an excellent space to have facilitated discussions along the supply chain, allowing members to 'lift the curtains' on what they want to do better, and how they can do it jointly. Whilst the industry is traditionally secretive to protect IP, there are many common challenges they can work on together. One such challenge is the responsible use of single-use technology.

BioPhorum members recognize the need to transform the performance of the global supply chain for biologics, and so a team of subject matter experts from across multiple companies are shaping a program of cross-industry collaboration to address topics ranging from capacity constraints, increased costs, and alignment on quality expectations of the outbound supply chain.

Lesley Holt, BioPhorum Supply Chain to Patient Director, discusses freight capacity and increased costs, complexity of supply chains for cell and gene therapy and direct to patient, and the benefits of collaboration on influencing regulations.

Sustainability for many organizations is mission-critical and materials science group Corning is making great progress. Most recently, using guidance developed by the Science Based Targets initiative (SBTi) and in alignment with a 1.5°C future scenario, two more goals were added to their list of climate commitments: reduce Scope 1 and 2 greenhouse gas (GHG) emissions by 30% (absolute basis) and relevant Scope 3 emissions by 17.5% (absolute basis) by 2028 compared to a 2021 baseline.

In this podcast, Christie McCarthy, Director of Sustainability at Corning Life Sciences, talks about being the conductor of a sustainability orchestra, building on from pockets of goodness, connecting the dots between employees and impact, and the importance of industry engagement.

Bob Brooks, BioPhorum Supply Partner Lead and Clare Simpson, BioPhorum Technology Roadmapping Lead share their thoughts on the recent focus on a new strategy.

Answering questions about why BioPhorum published the new technology vision and how this instructed a need for a strategic framework.

Tara Cox, Head of Device Quality and Regulatory Compliance at Takeda talks us through the updated EU MDR regulation, the drivers that instructed the update and the biggest changes that will impact the biopharmaceutical industry. How is BioPhorum helping to address the challenges that are anticipated in supporting the products?